Umoja Biopharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
191
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$100M
- Investors
-
23
Umoja Biopharma General Information
Description
Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and delivers to any patient, with any tumor, at any time to directly, safely, and controllably attack cancer, enabling medical practitioners to safeguard patients by creating and harnessing a powerful immune response in the body.
Contact Information
Website
www.umoja-biopharma.comCorporate Office
- 1150 Eastlake Avenue East
- Suite 400
- Seattle, WA 98109
- United States
Corporate Office
- 1150 Eastlake Avenue East
- Suite 400
- Seattle, WA 98109
- United States
Umoja Biopharma Timeline
Umoja Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 03-Oct-2024 | $100M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series B) | 15-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 18-Nov-2020 | $53M | $61M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 21-Nov-2019 | $8M | $8M | Completed | Pre-Clinical Trials |
Umoja Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Series A | ||||||||
| Seed 1 | 565,996 | $0.000100 | $2.24 | $2.24 | 1x | $2 | 0.6% | |
| Seed | 2,400,773 | $0.000100 | $2.8 | $2.8 | 1x | $2.25 | 2.81% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Umoja Biopharma Comparisons
Industry
Financing
Details
Umoja Biopharma Competitors (57)
One of Umoja Biopharma’s 57 competitors is RootPath, a Venture Capital-Backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RootPath | Venture Capital-Backed | Watertown, MA | ||||
| Phio Pharmaceuticals | Formerly Accelerator/Incubator backed | Marlborough, MA | ||||
| T3 Pharmaceuticals | Formerly VC-backed | Allschwil, Switzerland | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Umoja Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Umoja Biopharma Patents
Umoja Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023314782-A1 | Differentiation of stem cells in suspension culture | Pending | 27-Jul-2022 | ||
| AU-2023283552-A1 | Engineered stem cells and uses thereof | Pending | 10-Jun-2022 | ||
| AU-2023285113-A1 | Compositions and methods for nk cell differentiation | Pending | 09-Jun-2022 | ||
| AU-2023272490-A1 | Manufacturing viral particles | Pending | 17-May-2022 | ||
| AU-2023265993-A1 | Viral particle with surface stimulating molecules | Pending | 06-May-2022 | C12N15/86 |
Umoja Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Umoja Biopharma Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARK Investment Management | Asset Manager | Minority | ||
| ARK Venture Fund | Venture Capital | Minority | ||
| Double Point Ventures | Venture Capital | Minority | ||
| K2 HealthVentures | Venture Capital | Minority | ||
| Myeloma Investment Fund | Not-For-Profit Venture Capital | Minority |
Umoja Biopharma FAQs
-
When was Umoja Biopharma founded?
Umoja Biopharma was founded in 2019.
-
Where is Umoja Biopharma headquartered?
Umoja Biopharma is headquartered in Seattle, WA.
-
What is the size of Umoja Biopharma?
Umoja Biopharma has 191 total employees.
-
What industry is Umoja Biopharma in?
Umoja Biopharma’s primary industry is Biotechnology.
-
Is Umoja Biopharma a private or public company?
Umoja Biopharma is a Private company.
-
What is the current valuation of Umoja Biopharma?
The current valuation of Umoja Biopharma is .
-
What is Umoja Biopharma’s current revenue?
The current revenue for Umoja Biopharma is .
-
How much funding has Umoja Biopharma raised over time?
Umoja Biopharma has raised $371M.
-
Who are Umoja Biopharma’s investors?
ARK Investment Management, ARK Venture Fund, Double Point Ventures, K2 HealthVentures, and Myeloma Investment Fund are 5 of 23 investors who have invested in Umoja Biopharma.
-
Who are Umoja Biopharma’s competitors?
RootPath, Phio Pharmaceuticals, T3 Pharmaceuticals, Aro Biotherapeutics, and Kite Pharma are some of the 57 competitors of Umoja Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
